Nevirapine Extended Release (Alvogen Inc.)
Welcome to the PulseAid listing for the Nevirapine Extended Release drug offered from Alvogen Inc.. This Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Analog [Chemical/Ingredient],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA],Cytochrome P450 3A Inducers [MoA],Cytochrome P450 2B6 Inducers [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Alvogen Inc. |
| NON-PROPRIETARY NAME: | nevirapine |
| SUBSTANCE NAME: | NEVIRAPINE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Analog [Chemical/Ingredient],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA],Cytochrome P450 3A Inducers [MoA],Cytochrome P450 2B6 Inducers [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET |
| MARKETING CATEGORY NAME: | ANDA |
| START MARKETING DATE: | 2015-07-14 |
| END MARKETING DATE: | 0000-00-00 |
Nevirapine Extended Release HUMAN PRESCRIPTION DRUG Details:
| Item Description | Nevirapine Extended Release from Alvogen Inc. |
| LABELER NAME: | Alvogen Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 400(mg/1) |
| START MARKETING DATE: | 2015-07-14 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 47781-317_beca55f4-2f47-256c-414d-ec9f6ef9fcb0 |
| PRODUCT NDC: | 47781-317 |
| APPLICATION NUMBER: | ANDA204621 |
Other NEVIRAPINE Pharmaceutical Manufacturers / Labelers:
